Crossmark

Efficacy and safety of Atusin® CAP in the treatment of acute uncomplicated bronchitis in the primary care setting: a multi-center, randomized, double-blind, placebo-controlled study (AABA)

Crossref DOI link: https://doi.org/10.1186/s12890-025-03912-6

Published Online: 2025-10-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Petkova, Diana

Petkov, Rosen

Hodzhev, Vladimir https://orcid.org/0000-0002-4476-2088
Ivanov, Yavor

Hadjiev, Veselin
License Information

Text and Data Mining valid from 2025-10-01

Version of Record valid from 2025-10-01
More Information

Article History

Received: 10 April 2025

Accepted: 20 August 2025

First Online: 1 October 2025

Declarations

:

: The authors declare no competing interests.

: The protocol and informed consent form were reviewed and approved by an independent ethics committee prior to enrollment of any participants in the study (The Research Ethics Committee of the Medical University of Sofia (KENIMUS), Bulgaria approved the study procedures (Approval No 02/23.01.2024). Informed consent to participate in the study was obtained from all participants and their privacy rights were observed. The study was conducted in compliance with the protocol and according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines, the Helsinki Declaration of 1964 and its later amendments, and applicable confidentiality laws.

: Not applicable.

Document is current

Any future updates will be listed below